Medical Device
IDRx Secures $120M for Pivotal KIT Inhibitor Study with Promising Early Data
IDRx, KIT inhibitor, pivotal study, funding, cancer treatment, biotech
Mallinckrodt Sells Immunotherapy Business to CVC Capital for $925 Million
Mallinckrodt, CVC Capital, immunotherapy, Therakos, $925 million deal
Mallinckrodt to Sell Therakos Business Unit to CVC Capital for $925 Million
Mallinckrodt, Therakos, CVC Capital Partners, photopheresis, extracorporeal photopheresis, ECP, cutaneous T-cell lymphoma, CTCL, immunotherapy, pharmaceuticals, medical technology, healthcare services
Dexcom Stock Plummets 40% After Disappointing CGM Sales and Weak Guidance
Dexcom, CGM, Sales Challenges, Stock Drop, Weak Guidance
Biopharma Layoff Tracker 2024: Anokion, GlycoMimetics, Relay and More Cut Staff
Biopharma, Layoffs, 2024, Anokion, GlycoMimetics, Relay, Restructuring, Job Cuts, Industry Trends
Bluebird Bio’s Fertility Support Program for Gene Therapies Rejected by HHS Inspector General
Bluebird Bio, Gene Therapy, Fertility Support, HHS Inspector General, Zynteglo, Skysona, Anti-Kickback Rules
Orexo’s Opioid Overdose Nasal Spray Fails FDA Review for Second Time
Orexo, OX124, FDA, Nasal Spray, Opioid Overdose, Naloxone, Human Factors Study, Technical Data
US FTC Intensifies Patent Crusade with Investigation into Teva’s Inhaler IP
US Federal Trade Commission, Teva Pharmaceuticals, Patent Investigation, Inhaler IP, Anticompetitive Practices, Generic Competition
Revolutionizing Public Health: CBER’s Peter Marks and the Vision to Reduce FDA Visits
CBER, Peter Marks, FDA, public health, healthcare innovation, regulatory affairs, biologics, vaccines, medical devices, preventive measures.
BenevolentAI Announces Significant Restructuring with Workforce Reduction and US Office Closure
BenevolentAI, restructuring, workforce reduction, US office closure, reset, artificial intelligence, biotechnology, drug discovery